ArticleRespiration; international review of thoracic diseases2026
Development of a Physician-Independent Screening for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Case-Control and Cohort Study.
Article in Respiration; international review of thoracic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInterstitial lung disease (ILD) is a leading cause of death in rheumatoid arthritis (RA) patients. Given RA's high prevalence, a physician-independent screening tool is needed. This study aimed to develop a patient-based, cost-effective questionnaire for RA-associated ILD (RA-ILD).
methodsA 26-item ILD symptom questionnaire was evaluated, adapted, and validated in two steps. Missing data were handled via multiple imputation. Step one involved item and principal component analyses in a multicenter cohort of ILD patients and healthy controls. Internal consistency was measured with McDonald's omega, and score differences assessed with independent t tests and Cohen's d. Step two validated the questionnaire in monocentrically recruited anti-citrullinated protein antibodies- and rheumatoid factor-positive RA patients without prior pulmonary exams. RA-ILD was defined as abnormal lung ultrasound across 14 intercostal spaces with forced vital capacity or DLCO <80% predicted. ROC, sensitivity, and specificity were calculated.
resultsStep one included 174 ILD patients (46% female, mean age 62 ± 13, mean score 39 [95% CI: 35-43]) and 67 controls (49% female, mean age 59 ± 12, mean score 8 [95% CI: 4-12]). Internal consistency was excellent (ω = 0.93). Scores differed significantly (t = -11.71, p < 0.001, d = 1.36). Step two included 105 RA patients (76% female, mean age 59 ± 12, mean disease duration 9 ± 6 years, mean score 14 [95% CI: 10-17]); 11 were suspected of RA-ILD (mean score 18 [95% CI: 8-28]). A cut-off of 7.5 points yielded ROC 0.58, sensitivity 70.3%, specificity 47.7%, positive predictive value 13.6%, and negative predictive value 93.2%.
conclusionThe questionnaire demonstrated potential as a physician-independent, low-cost RA-ILD screening tool suitable for routine clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.